Zacks: Brokerages Expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to Announce -$0.74 Earnings Per Share

Brokerages expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to report ($0.74) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.79) and the highest is ($0.70). Kala Pharmaceuticals posted earnings of ($0.60) per share during the same quarter last year, which indicates a negative year over year growth rate of 23.3%. The firm is scheduled to report its next earnings report on Thursday, August 8th.

On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($2.86) per share for the current fiscal year, with EPS estimates ranging from ($3.03) to ($2.71). For the next year, analysts anticipate that the company will report earnings of ($1.86) per share, with EPS estimates ranging from ($2.48) to ($0.58). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.75). The company had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.96 million.

Several analysts have weighed in on the company. Wedbush set a $51.00 price objective on Kala Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 5th. Oppenheimer started coverage on Kala Pharmaceuticals in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Zacks Investment Research lowered H&E Equipment Services from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, BidaskClub lowered Zogenix from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Kala Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $19.43.

NASDAQ:KALA traded down $0.16 on Friday, hitting $5.57. 90,971 shares of the stock were exchanged, compared to its average volume of 202,293. The firm has a market capitalization of $194.13 million, a PE ratio of -2.29 and a beta of 2.02. Kala Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $14.45. The company has a quick ratio of 9.93, a current ratio of 10.30 and a debt-to-equity ratio of 0.86. The business has a 50-day moving average of $5.79.

In other news, Director Howard B. Rosen purchased 5,000 shares of Kala Pharmaceuticals stock in a transaction on Thursday, May 30th. The stock was purchased at an average price of $5.42 per share, with a total value of $27,100.00. Following the transaction, the director now directly owns 8,240 shares in the company, valued at approximately $44,660.80. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 30.77% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in Kala Pharmaceuticals during the 1st quarter valued at approximately $325,000. Alambic Investment Management L.P. purchased a new position in shares of Kala Pharmaceuticals in the 1st quarter worth $344,000. Boston Partners purchased a new position in Kala Pharmaceuticals during the first quarter valued at $152,000. Rhumbline Advisers lifted its position in Kala Pharmaceuticals by 27.4% during the first quarter. Rhumbline Advisers now owns 19,430 shares of the company’s stock valued at $161,000 after purchasing an additional 4,174 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC purchased a new position in Kala Pharmaceuticals during the first quarter valued at $46,000. 69.92% of the stock is owned by institutional investors.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Recommended Story: Can systematic risk be avoided?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with's FREE daily email newsletter.